Objective To investigate the influence of hemoperfusion on inflammatory response and clinical effects in adult patients receiving extracorporeal membrane oxygenation (ECMO). Methods A total of 86 patients who received ECMO treatment were divided into observation group or control group by the random number table method, with 43 cases in each group. Patients of the control group received comprehensive therapy and ECMO therapy, based on which the observation group received hemoperfusion therapy. Clinical indices with respect to respiratory rate, heart rate, mean arterial pressure (MAP), body temperature, Acute Physiology and Chronic Health Evaluation Ⅱ (APACHEⅡ ) score at different time points, oxygenation index in terms of arterial partial pressure of oxygen (PaO2) /fraction of inspired oxygen (FiO2) at different time points, blood routine (white blood cell counts, hemoglobin and albumin levels, blood platelet counts) at different time points, serum inflammatory factors levels in terms of C⁃reactive protein (CRP), tumor necrosis factor α (TNF⁃α), interleukin (IL)⁃6, IL⁃10 at different time points, arterial blood gas indicators (arterial blood lactic acid ［LAC］ level, arterial oxygen saturation ［SaO2］) at different time points, as well as the occurrence of adverse events during treatment were compared between patients of the two groups. Results There were statistically significant differences in the respiratory rate, heart rate, MAP, APACHEⅡ score, PaO2/FiO2, white blood cell counts, hemoglobin level, albumin level, blood platelet counts, and levels of CRP, TNF⁃α, IL⁃6, IL⁃10, LAC, as well as SaO2 between the two groups (P<0.05). With the extension of the treatment time, the respiratory rate, heart rate, APACHEⅡ score, white blood cell counts, blood platelet counts and LAC level of the two groups exhibited a downward trend, while MAP, PaO2/FiO2, and levels of hemoglobin, albumin, CRP, TNF⁃α, IL⁃6, IL⁃10 and SaO2 depicted an upward trend (P<0.05). At 8 and 72 hours of treatment, the respiratory rate, heart rate, APACHEⅡ score, white blood cell counts, blood platelet counts, and levels of CRP, TNF⁃α, IL⁃6, IL⁃10 and LAC in the observation group were lower than those in the control group, while MAP, PaO2/FiO2, hemoglobin and albumin levels, as well as SaO2 were higher than those in the control group (P<0.05). There was no statistically significant difference in body temperature between the two groups (P>0.05), whereas the body temperature of the two groups expressed a trend of change with time, and the body temperature at 8 and 72 hours of treatment was lower than that before treatment (P<0.05). The total incidence rate of adverse events during treatment was lower in the observation group than in the control group (P<0.05). Conclusion Hemoperfusion can reduce the inflammatory response of adult patients receiving ECMO, maintain their hemodynamic stability, improve their blood routine and arterial blood gas indexes, enhance their oxygenation capacity, with good safety.

无